HRP20211322T1 - Derivati triazolo[4,5-d]pirimidina kao antagonisti cb2 receptora - Google Patents
Derivati triazolo[4,5-d]pirimidina kao antagonisti cb2 receptora Download PDFInfo
- Publication number
- HRP20211322T1 HRP20211322T1 HRP20211322TT HRP20211322T HRP20211322T1 HR P20211322 T1 HRP20211322 T1 HR P20211322T1 HR P20211322T T HRP20211322T T HR P20211322TT HR P20211322 T HRP20211322 T HR P20211322T HR P20211322 T1 HRP20211322 T1 HR P20211322T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- compound according
- morpholin
- pyrimidin
- chlorophenyl
- Prior art date
Links
- GIIGHSIIKVOWKZ-UHFFFAOYSA-N 2h-triazolo[4,5-d]pyrimidine Chemical class N1=CN=CC2=NNN=C21 GIIGHSIIKVOWKZ-UHFFFAOYSA-N 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- -1 trifluoromethylphenyl Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 230000000735 allogeneic effect Effects 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 125000005059 halophenyl group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 208000007788 Acute Liver Failure Diseases 0.000 claims 1
- 206010000804 Acute hepatic failure Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- TZLCCDLGDBZHEW-HXUWFJFHSA-N C[C@@]1(CN(CC1)C=1C2=C(N=C(N=1)N1CCOCC1)N(N=N2)CC1=C(C=CC=C1)C(F)(F)F)O Chemical compound C[C@@]1(CN(CC1)C=1C2=C(N=C(N=1)N1CCOCC1)N(N=N2)CC1=C(C=CC=C1)C(F)(F)F)O TZLCCDLGDBZHEW-HXUWFJFHSA-N 0.000 claims 1
- TZLCCDLGDBZHEW-FQEVSTJZSA-N C[C@]1(CN(CC1)C=1C2=C(N=C(N1)N1CCOCC1)N(N=N2)CC2=C(C=CC=C2)C(F)(F)F)O Chemical compound C[C@]1(CN(CC1)C=1C2=C(N=C(N1)N1CCOCC1)N(N=N2)CC2=C(C=CC=C2)C(F)(F)F)O TZLCCDLGDBZHEW-FQEVSTJZSA-N 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000032544 Cicatrix Diseases 0.000 claims 1
- QGZFQCJKMNJMCA-UHFFFAOYSA-N Clc1ccccc1Cn1nnc2c(nc(nc12)N1CCCCC1)N1CCCCC1 Chemical compound Clc1ccccc1Cn1nnc2c(nc(nc12)N1CCCCC1)N1CCCCC1 QGZFQCJKMNJMCA-UHFFFAOYSA-N 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- OVANEXOHIBDPDH-UHFFFAOYSA-N FC1(F)CCN(C1)c1nc(nc2n(Cc3ccccc3Cl)nnc12)N1CCC1 Chemical compound FC1(F)CCN(C1)c1nc(nc2n(Cc3ccccc3Cl)nnc12)N1CCC1 OVANEXOHIBDPDH-UHFFFAOYSA-N 0.000 claims 1
- SNDQMUVTJJQXKC-UHFFFAOYSA-N FC1(F)CCN(C1)c1nc(nc2n(Cc3ccccc3Cl)nnc12)N1CCOCC1 Chemical compound FC1(F)CCN(C1)c1nc(nc2n(Cc3ccccc3Cl)nnc12)N1CCOCC1 SNDQMUVTJJQXKC-UHFFFAOYSA-N 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010051920 Glomerulonephropathy Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023421 Kidney fibrosis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 231100000836 acute liver failure Toxicity 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000005133 alkynyloxy group Chemical group 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 125000000068 chlorophenyl group Chemical group 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 1
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000004439 haloalkylsulfanyl group Chemical group 0.000 claims 1
- 230000001969 hypertrophic effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 230000037387 scars Effects 0.000 claims 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (11)
1. Spoj formule (I),
[image]
naznačen time, da
R1 je haloalkil, halofenil, alkoksifenil, alkil-1,2,5-oksadiazolil, haloalkilfenil, alkilsulfonilfenil, halopiridinil ili alkiltetrazolil;
R2 je piperidinil, azetidinil, pirolidinil ili morfolinil;
R3 i R4 neovisno su odabrani iz vodika, halogena, hidroksila, alkilkarbonilamina i alkila pod uvjetom da R3 i R4 nisu vodik u isto vrijeme; i
n je 1 ili 2;
ili njihova farmaceutski prihvatljiva sol.
2. Spoj prema patentnom zahtjevu 1, naznačen time, da R1 je halofenil, haloalkilfenil ili alkilsulfonilfenil.
3. Spoj prema patentnom zahtjevu 1 ili 2, naznačen time, da R1 je klorofenil, trifluorometilfenil ili metilsulfonilfenil.
4. Spoj prema bilo kojem od patentnih zahtjeva od 1 do 3, naznačen time, da su R3 i R4 neovisno odabrani iz skupine koju čine vodik, halogen i hidroksil.
5. Spoj prema bilo kojem od patentnih zahtjeva od 1 do 4, naznačen time, da je jedan od R3 i R4 vodik, a drugi je hidroksil, ili time, da su R3 i R4 oba halogeni u isto vrijeme.
6. Spoj prema bilo kojem od patentnih zahtjeva od 1 do 5, naznačen time, da je jedan od R3 i R4 vodik, a drugi je hidroksil, ili time, da su R3 i R4 oba fluor u isto vrijeme.
7. Spoj prema bilo kojem od patentnih zahtjeva od 1 do 6, naznačen time, da je odabran iz skupine koju čine
3-[(2-klorofenil)metil]-5,7-di(piperidin-1-il)triazolo[4,5-d]pirimidin;
5-(azetidin-1-il)-3-[(2-klorofenil)metil]-7-(3,3-difluoropirolidin-1-il)triazolo[4,5-d]pirimidin;
3-[(2-klorofenil)metil]-7-(3,3-difluoropirolidin-1-il)-5-pirolidin-1-itriazolo[4,5-d]pirimidin;
4-[3-[(2-klorofenil)metil]-7-(3,3-difluoropirolidin-1-il)triazolo[4,5-d]pirimidin-5-il]morfolin;
(3S)-1-[3-[(2-klorofenil)metil]-5-morfolin-4-itriazolo[4,5-d]pirimidin-7-il]-3-metilpirolidin-3-ol;
(3S)-3-metil-1-[5-morfolin-4-il-3-[[2-(trifluorometil)fenil]metil]triazolo[4,5-d]pirimidin-7-il]pirolidin-3-ol;
(3S)-1-[3-[(3-kloropiridin-2-il)metil]-5-morfolin-4-itriazolo[4,5-d]pirimidin-7-il]-3-metilpirolidin-3-ol;
(3S)-3-metil-1-[3-[(3-metil-1,2,4-oksadiazol-5-il)metil]-5-morfolin-4-itriazolo[4,5-d]pirimidin-7-il]pirolidin-3-ol;
(3R)-1-[3-[(2-klorofenil)metil]-5-morfolin-4-itriazolo[4,5-d]pirimidin-7-il]-3-metilpirolidin-3-ol;
(3R)-3-metil-1-[5-morfolin-4-il-3[[2-(trifluorometil)fenil]metil]triazolo[4,5-d]pirimidin-7-il]pirolidin-3-ol;
(3R)-3-metil-1-[3-[(2-metilsulfonilfenil)metil]-5-morfolin-4-itriazolo[4,5-d]pirimidin-7-il]pirolidin-3-ol; i
(3R)-3-metil-1-[3-[(3-metil-1,2,4-oksadiazol-5-il)metil]-5-morfolin-4-itriazolo[4,5-d]pirimidin-7-il]pirolidin-3-ol.
8. Postupak za pripremu spoja prema bilo kojem od patentnih zahtjeva od 1 do 7, naznačen time, da obuhvaća jedan od sljedećih koraka:
(a) reakciju spoja formule (A1)
[image]
u prisutnosti spoja formule (A2)
[image]
pri čemu R2 je izopropil, cikloalkil ili alkenil, a R1, R3, R4 i n su definirani u bilo kojem od patentnih zahtjeva od 1 do 7;
(b) reakciju spoja formule (B1)
[image]
u prisutnosti R1CH2X, pri čemu X je halogen, hidroksil ili skupina sulfonata, pri čemu R2 je izopropil, cikloalkil ili alkenil, i pri čemu su od R3 do R4 i n definirani u bilo kojem od patentnih zahtjeva od 1 do 7;
(c) reakciju spoja formule (C1)
[image]
u prisutnosti R2-H, pri čemu R2 je piperidinil, alkilamino, azetidinil, pirolidinil, cikloalkilamino, alkiloksetanilamino, morfolinil, (cikloalkil)(alkil)amino, haloalkiloksi, alkoksi, cikloalkilalkoksi, cikloalkiloksi, oksetaniloksi, alkiloksetanilalkiloksi, alkiniloksi, alkoksialkoksi, hidroksialkiloksi, alkilsulfanil, haloalkilsulfanil, alkilsulfonil, hidroksialkilsulfanil, hidroksialkilsulfonil ili alkoksialkilsulfonil, i pri čemu su R1, R3, R4 i n definirani u bilo kojem od patentnih zahtjeva od 1 do 7.
9. Spoj prema bilo kojem od patentnih zahtjeva od 1 do 7, koji se upotrebljava kao terapijski aktivna tvar.
10. Farmaceutski pripravak, naznačen time, da sadrži spoj prema bilo kojem od patentnih zahtjeva od 1 do 7 i terapijski inertni nosač.
11. Spoj prema bilo kojem od patentnih zahtjeva od 1 do 7, naznačen time, da se upotrebljava u liječenju ili profilaksi boli, ateroskleroze, starosne makularne degeneracije, dijabetičke retinopatije, glaukoma, šećerne bolesti (diabetes mellitus), upale, upalne bolesti crijeva, ishemijsko-reperfuzijskih ozljeda, akutnog zatajenja jetre, jetrene fibroze, plućne fibroze, fibroze bubrega, sustavne fibroze, akutnog odbacivanja alogenskog presatka, kronične alogenske nefropatije, dijabetičke nefropatije, glomerulonefropatije, kardiomiopatije, zatajenja srca, miokardijalne ishemije, infarkta miokarda, sustavne skleroze, toplinskih ozljeda, opeklina, hipertrofičnih ožiljaka, keloida, upale desni, vrućice, ciroze ili tumora jetre, regulacije koštane mase, neurodegenerativnih bolesti, moždanog udara, prolaznog ishemijskog napada ili uveitisa.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13183385 | 2013-09-06 | ||
| EP18206943.5A EP3483163B1 (en) | 2013-09-06 | 2014-09-03 | Triazolo[4,5-d]pyrimidine derivatives as cb2 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211322T1 true HRP20211322T1 (hr) | 2021-11-26 |
Family
ID=49111076
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190361TT HRP20190361T1 (hr) | 2013-09-06 | 2019-02-25 | Derivati triazolo[4,5-d]pirimidina kao antagonisti cb2 receptora |
| HRP20211322TT HRP20211322T1 (hr) | 2013-09-06 | 2021-08-16 | Derivati triazolo[4,5-d]pirimidina kao antagonisti cb2 receptora |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190361TT HRP20190361T1 (hr) | 2013-09-06 | 2019-02-25 | Derivati triazolo[4,5-d]pirimidina kao antagonisti cb2 receptora |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9593123B2 (hr) |
| EP (3) | EP3943497A1 (hr) |
| JP (1) | JP6441356B2 (hr) |
| KR (3) | KR102349567B1 (hr) |
| CN (1) | CN105555788B (hr) |
| AR (1) | AR097553A1 (hr) |
| AU (1) | AU2014317229B2 (hr) |
| CA (1) | CA2915766C (hr) |
| CL (1) | CL2016000495A1 (hr) |
| CR (1) | CR20160076A (hr) |
| DK (2) | DK3483163T3 (hr) |
| EA (1) | EA028335B1 (hr) |
| ES (2) | ES2883923T3 (hr) |
| HK (1) | HK1219277A1 (hr) |
| HR (2) | HRP20190361T1 (hr) |
| HU (2) | HUE041760T2 (hr) |
| IL (1) | IL243092B (hr) |
| LT (2) | LT3483163T (hr) |
| MA (1) | MA38826B1 (hr) |
| MX (2) | MX367084B (hr) |
| MY (1) | MY191628A (hr) |
| PE (2) | PE20160691A1 (hr) |
| PH (1) | PH12016500250A1 (hr) |
| PL (2) | PL3041843T3 (hr) |
| PT (2) | PT3483163T (hr) |
| RS (2) | RS58390B1 (hr) |
| SG (1) | SG11201601714UA (hr) |
| SI (2) | SI3041843T1 (hr) |
| TR (1) | TR201900662T4 (hr) |
| TW (1) | TWI705966B (hr) |
| UA (1) | UA116395C2 (hr) |
| WO (1) | WO2015032769A1 (hr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015162630A1 (en) * | 2014-04-25 | 2015-10-29 | Anlon Chemical Research Organization | Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis. |
| WO2016071375A1 (en) | 2014-11-07 | 2016-05-12 | F. Hoffmann-La Roche Ag | Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2 |
| WO2017004133A1 (en) * | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| WO2017076266A1 (zh) * | 2015-11-06 | 2017-05-11 | 江苏恒瑞医药股份有限公司 | 制备坎格雷洛中间体的方法 |
| CN109311886B (zh) | 2016-06-23 | 2021-11-09 | 豪夫迈·罗氏有限公司 | [1,2,3]三唑并[4,5-d]嘧啶衍生物 |
| SG10202113286RA (en) * | 2016-06-23 | 2021-12-30 | Hoffmann La Roche | [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor |
| JP7090037B2 (ja) * | 2016-06-23 | 2022-06-23 | エフ．ホフマン－ラ ロシュ アーゲー | 新規な［１，２，３］トリアゾロ［４，５－ｄ］ピリミジン誘導体 |
| EP3475283B1 (en) | 2016-06-23 | 2021-08-11 | F. Hoffmann-La Roche AG | Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives |
| CN106478639B (zh) * | 2016-09-05 | 2018-09-18 | 郑州大学 | 嘧啶并1,2,4–三氮唑类的lsd1抑制剂、其制备方法及应用 |
| CN106432247B (zh) * | 2016-09-27 | 2018-06-29 | 郑州大学 | 含有腙键的嘧啶并三氮唑类化合物、制备方法及其应用 |
| CN106432248B (zh) * | 2016-09-27 | 2018-11-27 | 郑州大学 | 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用 |
| CN106928296A (zh) * | 2017-02-06 | 2017-07-07 | 上海华升生物科技有限公司 | 一种2‑(3,3,3‑三氟丙硫基)腺苷的合成方法 |
| CN106928235A (zh) * | 2017-05-03 | 2017-07-07 | 郑州大学 | 含嘧啶并三氮唑类lsd1抑制剂、其制备方法及应用 |
| CN107033148B (zh) * | 2017-05-03 | 2018-10-26 | 郑州大学 | 含嘧啶并三氮唑—巯基四氮唑类lsd1抑制剂、其制备方法及应用 |
| CN109516990B (zh) * | 2017-09-19 | 2021-06-01 | 天津药物研究院有限公司 | 嘧啶并三氮唑类化合物、其制备方法和用途 |
| CN113582935A (zh) * | 2021-08-27 | 2021-11-02 | 中国医学科学院放射医学研究所 | 一种炎症小体核苷酸结合寡聚化结构域样受体蛋白3抑制剂及其制备方法和应用 |
| CN115246832A (zh) * | 2022-06-15 | 2022-10-28 | 深圳湾实验室 | 一类去泛素化酶usp25和usp28靶向抑制剂及制备和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1012151B1 (en) | 1997-09-02 | 2002-08-07 | Bristol-Myers Squibb Pharma Company | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders |
| CA2399791A1 (en) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| JP2008503464A (ja) * | 2004-06-17 | 2008-02-07 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 習慣性行動の１つ以上の構成要素の改善のためのアデノシンａ２ａレセプターの拮抗 |
| AR051596A1 (es) | 2004-10-26 | 2007-01-24 | Irm Llc | Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios |
| WO2008141249A1 (en) | 2007-05-10 | 2008-11-20 | Acadia Pharmaceuticals Inc. | Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors |
| EP2219646A4 (en) * | 2007-12-21 | 2010-12-22 | Univ Rochester | METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS |
| WO2009117444A1 (en) | 2008-03-17 | 2009-09-24 | Northeastern University | Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors |
| WO2010120987A1 (en) | 2009-04-17 | 2010-10-21 | Wyeth Llc | Ring fused, ureidoaryl- and carbamoylaryl-bridged morpholino-pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| WO2013060837A1 (en) | 2011-10-27 | 2013-05-02 | Lek Pharmaceuticals D.D. | Synthesis of triazolopyrimidine compounds |
| UA111640C2 (uk) * | 2011-11-08 | 2016-05-25 | Ф. Хоффманн-Ля Рош Аг | ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2 |
| US9067943B2 (en) * | 2011-11-25 | 2015-06-30 | Hoffmann-La Roche Inc. | [1,2,3]triazolo[4,5-D]pyrimidine derivatives |
| CN104395290A (zh) | 2012-07-04 | 2015-03-04 | 霍夫曼-拉罗奇有限公司 | 作为大麻素受体2激动剂的新金刚烷基衍生物 |
| US9303012B2 (en) | 2012-12-07 | 2016-04-05 | Hoffman-La Roche Inc. | Pyridine-2-amides useful as CB2 agonists |
| CN104837831B (zh) | 2012-12-07 | 2017-10-31 | 霍夫曼-拉罗奇有限公司 | 新的吡啶衍生物 |
| PE20151060A1 (es) | 2012-12-07 | 2015-07-25 | Hoffmann La Roche | Nuevos derivados de pirazina como agonistas del receptor cb2 |
| MX2015007156A (es) | 2012-12-07 | 2015-10-14 | Hoffmann La Roche | Piridina-2-amidas utiles como agonistas receptores de canabinoides 2 (cb2). |
| WO2014135507A1 (en) | 2013-03-07 | 2014-09-12 | F. Hoffmann-La Roche Ag | Novel pyrazol derivatives |
| KR20210145303A (ko) | 2013-05-02 | 2021-12-01 | 에프. 호프만-라 로슈 아게 | Cb2 수용체 작용제로서의 퓨린 유도체 |
| CA2907691A1 (en) | 2013-05-02 | 2014-11-06 | F. Hoffmann-La Roche Ag | Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists |
| EP3008055B1 (en) | 2013-06-11 | 2017-07-19 | F. Hoffmann-La Roche AG | Tetrazolone derivatives |
-
2014
- 2014-09-03 JP JP2016539509A patent/JP6441356B2/ja active Active
- 2014-09-03 CN CN201480048593.7A patent/CN105555788B/zh active Active
- 2014-09-03 AU AU2014317229A patent/AU2014317229B2/en active Active
- 2014-09-03 HU HUE14761320A patent/HUE041760T2/hu unknown
- 2014-09-03 PL PL14761320T patent/PL3041843T3/pl unknown
- 2014-09-03 KR KR1020167008516A patent/KR102349567B1/ko active IP Right Grant
- 2014-09-03 LT LTEP18206943.5T patent/LT3483163T/lt unknown
- 2014-09-03 TR TR2019/00662T patent/TR201900662T4/tr unknown
- 2014-09-03 SI SI201431099T patent/SI3041843T1/sl unknown
- 2014-09-03 KR KR1020227034655A patent/KR20220140651A/ko not_active Application Discontinuation
- 2014-09-03 SG SG11201601714UA patent/SG11201601714UA/en unknown
- 2014-09-03 ES ES18206943T patent/ES2883923T3/es active Active
- 2014-09-03 EP EP21179163.7A patent/EP3943497A1/en active Pending
- 2014-09-03 WO PCT/EP2014/068640 patent/WO2015032769A1/en active Application Filing
- 2014-09-03 HU HUE18206943A patent/HUE055201T2/hu unknown
- 2014-09-03 PT PT182069435T patent/PT3483163T/pt unknown
- 2014-09-03 DK DK18206943.5T patent/DK3483163T3/da active
- 2014-09-03 RS RS20190264A patent/RS58390B1/sr unknown
- 2014-09-03 ES ES14761320T patent/ES2714094T3/es active Active
- 2014-09-03 SI SI201431869T patent/SI3483163T1/sl unknown
- 2014-09-03 EA EA201690478A patent/EA028335B1/ru not_active IP Right Cessation
- 2014-09-03 UA UAA201603048A patent/UA116395C2/uk unknown
- 2014-09-03 PL PL18206943T patent/PL3483163T3/pl unknown
- 2014-09-03 MY MYPI2016700721A patent/MY191628A/en unknown
- 2014-09-03 EP EP14761320.2A patent/EP3041843B1/en active Active
- 2014-09-03 EP EP18206943.5A patent/EP3483163B1/en active Active
- 2014-09-03 PE PE2015002700A patent/PE20160691A1/es unknown
- 2014-09-03 KR KR1020217017887A patent/KR102454344B1/ko active Application Filing
- 2014-09-03 RS RS20211007A patent/RS62234B1/sr unknown
- 2014-09-03 PE PE2019001869A patent/PE20191528A1/es unknown
- 2014-09-03 DK DK14761320.2T patent/DK3041843T3/en active
- 2014-09-03 PT PT14761320T patent/PT3041843T/pt unknown
- 2014-09-03 LT LTEP14761320.2T patent/LT3041843T/lt unknown
- 2014-09-03 MX MX2016002117A patent/MX367084B/es active IP Right Grant
- 2014-09-03 CA CA2915766A patent/CA2915766C/en active Active
- 2014-09-04 AR ARP140103305A patent/AR097553A1/es active IP Right Grant
- 2014-09-04 TW TW103130651A patent/TWI705966B/zh active
-
2015
- 2015-12-14 IL IL243092A patent/IL243092B/en active IP Right Grant
-
2016
- 2016-02-04 MA MA38826A patent/MA38826B1/fr unknown
- 2016-02-04 PH PH12016500250A patent/PH12016500250A1/en unknown
- 2016-02-16 CR CR20160076A patent/CR20160076A/es unknown
- 2016-02-17 MX MX2019009100A patent/MX2019009100A/es unknown
- 2016-02-23 US US15/050,753 patent/US9593123B2/en active Active
- 2016-03-04 CL CL2016000495A patent/CL2016000495A1/es unknown
- 2016-06-23 HK HK16107348.6A patent/HK1219277A1/zh unknown
-
2019
- 2019-02-25 HR HRP20190361TT patent/HRP20190361T1/hr unknown
-
2021
- 2021-08-16 HR HRP20211322TT patent/HRP20211322T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211322T1 (hr) | Derivati triazolo[4,5-d]pirimidina kao antagonisti cb2 receptora | |
| HRP20171099T1 (hr) | Derivati pirolo[2,3-d]pirimidina kao agonisti cb2 receptora | |
| ES2629414T3 (es) | Derivados de tiazol | |
| JP6218260B2 (ja) | Ｊａｋ阻害剤としてのアミノピリミジニル化合物 | |
| AU2017226004B2 (en) | Inhibitors of WDR5 protein-protein binding | |
| HRP20180371T1 (hr) | Novi derivati piridina | |
| AU2012299080B2 (en) | Pyrimidine PDE10 inhibitors | |
| TW201033206A (en) | S1P1 agonists and methods of making and using | |
| CA2886263A1 (en) | Heteroaryl inhibitors of pde4 | |
| TR201809417T4 (tr) | Cb2 reseptör agonistleri olarak purin türevleri. | |
| KR20180108822A (ko) | Nr2b-선택적 nmda 조절제로서 치환된 1,2,3-트라이아졸 | |
| JP6284545B2 (ja) | Ｃｆｔｒ阻害としての三環式化合物 | |
| HRP20151423T1 (hr) | DERIVATI [1,2,3]TRIAZOLO[4,5-d]PIRIMIDINA KAO AGONISTI RECEPTORA KANABINOIDA 2 | |
| JP2017533918A (ja) | カンナビノイド受容体２のアゴニストとしてのトリアゾロ［４，５−ｄ］ピリミジン | |
| JP2017522355A (ja) | 置換二環式ジヒドロピリミジノン及び好中球エラスターゼ活性の阻害薬としてのそれらの使用 | |
| CN116917279A (zh) | Btk抑制剂 | |
| BR112016004934B1 (pt) | Novos derivados de triazolo [4,5-d] pirimidina | |
| BR122020008944B1 (pt) | Novos derivados de triazolo [4,5-d] pirimidina | |
| NZ715085B2 (en) | Novel triazolo[4,5-d]pyrimidine derivatives | |
| NZ621245B2 (en) | Pyrimidine pde10 inhibitors | |
| NZ622652A (en) | [1,2,3] triazolo [4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 |